Literature DB >> 20868995

Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance.

Liping Su1, Ying Wang, Mingzhen Xiao, Yuan Lin, Lei Yu.   

Abstract

Survivin, a key member of the inhibitor of apoptosis protein family, has been reported to be capable of regulating both cellular proliferation and apoptotic cell death. This protein is found to be overexpressed in many human cancers. The aim of this study was to evaluate the prognostic significance of survivin mRNA expression in oral squamous cell carcinoma (OSCC) and to analyze its correlation with chemoresistance. Reverse-transcription polymerase chain reaction assay was performed to detect the expression of survivin mRNA in OSCC cell lines or tissue samples. Immunohistochemistry was performed to detect the expression of survivin protein in OSCC tissues or corresponding nontumor tissues. Then the correlation between survivin mRNA expression and clinicopathologic features or prognosis of OSCC patients was analyzed. Small interfering RNA technology was used to down-regulate the expression of the survivin gene in the OSCC cell line. Methylthiazol tetrazolium and flow cytometric assays were performed to detect proliferation and apoptosis of the OSCC cell line (HSC-3). Furthermore, the effect of small interfering RNA (siRNA) targeting survivin on the sensitivity of OSCC cells to chemotherapeutic agents (cisplatin and 5-fluorouracil [5-FU]) was determined. Results showed that the levels of survivin mRNA expression were significantly higher in OSCC cells or tissues than those in normal human oral keratinocyte or corresponding noncancerous tissues. The immunostaining of survivin protein was significantly stronger in OSCC tissues than in corresponding nontumor tissues. Moreover, high survivin mRNA expression was correlated with poorer tumor differentiation, higher clinical stage, and the presence of lymph node metastasis (P < .05). Multivariate analysis showed that the status of survivin mRNA could be an independent prognostic factor for OSCC patients (hazard ratio 2.71, 95% confidence interval 1.46-5.10; P = .012). In addition, siRNA-mediated survivin down-regulation could significantly inhibit proliferation and induce apoptosis of OSCC cells. Suvivin down-regulation could also significantly enhance chemosensitivity of OSCC cells, which was associated with apoptosis enhancement. Thus, the status of survivin mRNA expression was a potential prognostic factor for OSCC patients, and siRNA-mediated survivin down-regulation could become a novel strategy for chemosensitization of human OSCCs.
Copyright © 2010. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20868995     DOI: 10.1016/j.tripleo.2010.04.009

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  23 in total

1.  Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.

Authors:  Mathias Fiedler; Florian Weber; Matthias G Hautmann; Frank Haubner; Torsten E Reichert; Christoph Klingelhöffer; Stephan Schreml; Johannes K Meier; Arndt Hartmann; Tobias Ettl
Journal:  Clin Oral Investig       Date:  2017-03-18       Impact factor: 3.573

2.  BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.

Authors:  Julija Hmeljak; Nina Erčulj; Vita Dolžan; Izidor Kern; Andrej Cör
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-23       Impact factor: 4.553

Review 3.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective.

Authors:  Anubhav Jain; Saurabh Bundela; Ram P Tiwari; Prakash S Bisen
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

5.  Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma.

Authors:  Laura Bongiovanni; Francesca Mazzocchetti; Daniela Malatesta; Mariarita Romanucci; Andrea Ciccarelli; Paolo Buracco; Raffaella De Maria; Chiara Palmieri; Marina Martano; Emanuela Morello; Lorella Maniscalco; Leonardo Della Salda
Journal:  BMC Vet Res       Date:  2012-06-11       Impact factor: 2.741

6.  Survivin regulates the expression of VEGF-C in lymphatic metastasis of breast cancer.

Authors:  Xiaopeng Cai; Shuai Ma; Ming Gu; Cong Zu; Wenzhi Qu; Xinyu Zheng
Journal:  Diagn Pathol       Date:  2012-05-18       Impact factor: 2.644

7.  YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.

Authors:  Bhavna Kumar; Arti Yadav; James C Lang; Michael J Cipolla; Alessandra C Schmitt; Nicole Arradaza; Theodoros N Teknos; Pawan Kumar
Journal:  Mol Cancer Ther       Date:  2012-06-21       Impact factor: 6.009

8.  Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis.

Authors:  Bhavna Kumar; Arti Yadav; James Lang; Theodoros N Teknos; Pawan Kumar
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

9.  Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.

Authors:  Annelies W Turksma; Hetty J Bontkes; Janneke J Ruizendaal; Kirsten B J Scholten; Johanneke Akershoek; Shakila Rampersad; Laura M Moesbergen; Saskia A G M Cillessen; Saskia J A M Santegoets; Tanja D de Gruijl; C René Leemans; Chris J L M Meijer; Erik Hooijberg
Journal:  J Transl Med       Date:  2013-06-20       Impact factor: 5.531

10.  An indirubin derivative, indirubin-3'-monoxime suppresses oral cancer tumorigenesis through the downregulation of survivin.

Authors:  Wan-Yu Lo; Nai-Wen Chang
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.